Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.64 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5302518 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL527594 | 1.00 | P4HTM (0.64) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL17158147 | 0.84 | P4HTM (0.46) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL17158143 | 0.84 | P4HTM (0.46) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL15839225 | 0.84 | CCNC (0.46) | P4HTMAKR1B10AKR1B1AKR1C3AKR1C2 | |
| SCHEMBL8731557 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL6853074 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL11660063 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL11660064 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 | |
| SCHEMBL29789035 | 0.81 | P4HTM (0.68) | P4HTMHCAR2CA12AKR1B10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-2931734-B1 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-3321261-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| EP-2598480-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2019-04-24 | — | — | EP | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| EP-2776394-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-2054411-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-12-18 | — | — | US | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |
| EP-1882687-A1 | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same | Amorepacific Corporation (KR) | 2008-01-30 | — | — | EP | disclosed |
| WO-2007015744-A1 | DISUBSTITUTED THIENYL COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015744-A1 | DISUBSTITUTED THIENYL COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | P4HTM 1075/4885HCAR2 242/4885CA12 3264/4885 |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | P4HTM 152/4885HCAR2 361/4885CA12 4324/4885 |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | P4HTM 314/4885HCAR2 85/4885CA12 4776/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | P4HTM 267/4885HCAR2 343/4885CA12 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.